|
|
||||||||
1 Department of Pharmacology and Cell Biophysics and 2 Division of Cardiology, University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0542
| |
ABSTRACT |
|---|
|
|
|---|
Phospholamban levels regulate cardiac
sarcoplasmic reticulum Ca2+ pump
activity and myocardial contractility. To determine whether and to what
extent phospholamban modulates the force-frequency relation and
ventricular relaxation in vivo, we studied transgenic mice
overexpressing phospholamban (PLBOE), gene-targeted mice without
phospholamban (PLBKO), and isogenic wild-type controls. Contractility
was assessed by the peak rate of left ventricular (LV) isovolumic
contraction
(+dP/dtmax),
and diastolic function was assessed by both the peak rate
(
dP/dtmax)
and the time constant (
) of isovolumic LV relaxation, using a
high-fidelity LV catheter. Incremental atrial pacing was
used to generate heart rate vs.
dP/dtmax
(force-frequency) relations. Biphasic force-frequency relations were
produced in all animals, and the critical heart rate
(HRcrit) was taken as the heart
rate at which
dP/dtmax was maximal. The average LV
+dP/dtmax
increased in both PLBKO and PLBOE compared with their isogenic controls
(both P < 0.05). The HRcrit for LV
+dP/dtmax was
significantly higher in PLBKO (427 ± 20 beats/min) compared with
controls (360 ± 18 beats/min), whereas the
HRcrit in PLBOE (340 ± 30 beats/min) was significantly lower compared with that in isogenic
controls (440 ± 25 beats/min). The intrinsic heart rates were
significantly lower, and the
HRcrit and the
±dP/dtmax at
HRcrit were significantly greater
in FVB/N than in SvJ control mice. We conclude that
1) the level of phospholamban is a
critical negative determinant of the force-frequency relation and
myocardial contractility in vivo, and
2) contractile parameters may differ
significantly between strains of normal mice.
treppe; myocardial contractility; hemodynamics
| |
INTRODUCTION |
|---|
|
|
|---|
THE ADVANCES OF MOLECULAR biology and the development of gene targeting and transgenic technologies in the mouse have exponentially increased our understanding of cardiovascular physiology and pathophysiology (4, 13, 15, 31). Although a number of sophisticated in vitro and in vivo techniques are currently available to assess cardiac function in genetically engineered murine models, these methods are not without limitations (4, 15). The recent development of miniaturized catheter-based approaches to evaluate left ventricular (LV) function in both the open- and closed-chest mouse allows a more precise evaluation of in vivo cardiac function (12, 23, 28, 30). However, studies from several laboratories have shown that heart rate is an important determinant of cardiac contractility (1, 2, 8, 20, 27, 28, 32), and thus caution must be exercised when evaluating cardiac function in genetically engineered mice with variable heart rates.
The ability to systematically assess the effects of varying heart rates on cardiac contractility has demonstrated that the force-frequency relation is a powerful modulator of myocardial function in intact open- and closed-chest anesthetized mice (12, 28). We and others (12, 20) recently demonstrated that the relationship between paced heart rate and the peak rate of isovolumic contraction (±dP/dtmax) is biphasic, with both ascending and descending limbs, and that the force-frequency relation can be characterized by the heart rate at which dP/dtmax is maximal [the critical heart rate (HRcrit) (12, 20)]. Although altered Ca2+ homeostasis has been implicated in the genesis of the force-frequency relation (8, 12), the underlying molecular mechanisms remain uncertain.
Phospholamban is a 52-amino acid integral sarcoplasmic reticulum (SR) membrane phosphoprotein, which in its dephosphorylated state is an inhibitor of the apparent affinity of the SR Ca2+-ATPase for Ca2+; phosphorylation by protein kinases relieves this inhibition (16). The role of phospholamban in modulating cardiac contractility was recently elucidated by the generation of phospholamban gene-targeted and transgenic mice with cardiac specific overexpression of phospholamban (17, 24). An inverse correlation exists between the levels of phospholamban and cytosolic Ca2+ transients such that ablation of phospholamban results in an increase, whereas twofold cardiac-specific overexpression of phospholamban results in a decrease, in the amplitude of the Ca2+ transient (17, 21, 24).
Recently,
-adrenergic-mediated increases in
HRcrit were demonstrated in the
anesthetized mouse (28); shifts in the force-frequency relation may
have been mediated by catecholamine-induced phosphorylation (and hence
disinhibition) of phospholamban. However, the effects of catecholamines
are not specific. Thus the present study was designed to specifically
investigate the effect of ablation and overexpression of phospholamban
[with well-characterized concomitant alterations in intracellular
Ca2+ homeostasis, myocardial
contractility, and relaxation (17, 24)] on the force-frequency
relation in anesthetized closed-chest mice. Specifically, we tested the
hypothesis that the level of phospholamban is an important negative
determinant of the force-frequency relation such that ablation of
phospholamban enhances, whereas overexpression of phospholamban
depresses, the HRcrit in
anesthetized closed-chest mice.
| |
METHODS |
|---|
|
|
|---|
Generation of genetically engineered mice. The phospholamban knockout mice were produced with gene-targeting technology as previously described (24). Wild-type mice of identical mixed background were bred simultaneously with the phospholamban knockout animals. Mice with cardiac-specific overexpression of phospholamban were generated as previously described (17).
Inasmuch as the genetic background of the phospholamban knockout differs from that of the phospholamban overexpression mice, we thought it was important to compare hemodynamic data from each animal model with the appropriate wild-type controls. Thus the phospholamban knockout mice were processed in parallel with age-matched wild-type littermates (129SvJ), whereas the phospholamban overexpression mice were compared with their isogenic wild-type littermates (FVB/N).Animal preparation. Phospholamban knockout and phospholamban overexpression mice along with their respective isogenic wild-type littermates were instrumented as previously described (12). Briefly, mice were anesthetized with a mixture of ketamine (100 mg/kg), xylazine (5 mg/kg), and morphine (2.5 mg/kg), 0.1 ml/10 g intraperitoneally, intubated with a 24-gauge Jelco intravenous catheter, and ventilated at 100 cycles/min. The right jugular vein was isolated, and a 1-Fr bipolar pacing wire (NuMED, Nicholville, NY) was positioned in the right atrium. Flame-stretched Nalgene tubing was advanced into the right jugular vein for intravenous access. The right carotid artery was isolated and cannulated with a 1.4-Fr high-fidelity micromanometer (Millar, Houston, TX), which was then advanced into the left ventricle and secured with 6-0 silk.
Experimental protocol. Studies were performed in 26 animals (23-32 g) of either sex. There were six phospholamban overexpression and eight FVB/N controls, and six phospholamban knockouts and six 129SvJ controls.
After hemodynamic stability was ensured, baseline data were obtained in the intrinsic state and with the atrial pacemaker set at 5 Hz (300 beats/min). The sinus node fuzzy channel current inhibitor DKAH-0269 (0.1 ml iv, Boehringer Ingelheim, Ridgefield, CT) was given if the intrinsic heart rate was >300 beats/min. Atrial pacing was initiated just above intrinsic heart rate (or 300 beats/min) using a stimulator (model S88, Grass, West Warwick, RI), which was set at 3-4 V, 2 m/s pulse-width duration, and increased by 12 beats/min increments until LV dP/dtmax was visually decreased or until atrioventricular block unresponsive to 0.04-0.08 ng/g atropine supervened (HRcrit).Western blotting. Cardiac homogenates from 129SvJ and FVB/N wild-type mice were processed in parallel for quantitative immunoblotting analysis as previously described (17). Briefly, homogenates were separated on a 13% SDS polyacrylamide gel, electroblotted onto nitrocellulose membranes (Schleicher and Schuell, Keene, NH), probed with either a SR Ca2+-ATPase polyclonal antibody or an anti-phospholamban monoclonal antibody (Affinity BioReagents), and visualized using the enhanced chemiluminescence kit (Amersham). The levels of SR Ca2+-ATPase and phospholamban were quantitated using the ImageQuant analysis software.
Methods of analysis.
Analog signals of LV systolic pressure (LVSP) and LV end-diastolic
pressure (LVEDP) and peak rates of isovolumic contraction (+dP/dtmax) and
relaxation
(
dP/dtmax)
obtained by electronic differentiation of the LV pressure signal were
recorded online using a Gould WindowGraf four-channel recorder (Gould,
Cleveland, OH) and digitized via an analog-to-digital board at 1,000 Hz.
) was derived from
high-fidelity LV tracing, assuming a monoexponential decay of LV
pressure to a zero asymptote (37).
Statistical analysis. Data are expressed as means ± SE. Hemodynamic data were compared between FVB/N and phospholamban overexpression mice and phospholamban knockout and 129SvJ mice using unpaired t-tests, respectively. ANOVA was used to compare the LV ±dP/dtmax at initial-, critical-, and final-paced heart rates. Phospholamban and Ca2+-ATPase were expressed as a ratio (to account for variability in gel loading) and compared with unpaired t-tests. P < 0.05 was considered statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Baseline hemodynamics.
Hemodynamic parameters in the phospholamban knockout, phospholamban
overexpression, and their isogenic wild-type mice were examined under
both basal conditions and at an atrially paced rate of 300 beats/min
(Tables 1 and
2). The heart rate under basal conditions,
LVSP, and
+dP/dtmax were
significantly greater, and the time constant (
) was significantly
less in the phospholamban knockout mice compared with isogenic
controls. In contrast, the heart rate, LVSP, and
+dP/dtmax were
not significantly different in the phospholamban overexpression mice
compared with isogenic controls. However, at matched paced heart rates
of 300 beats/min, LVSP and
±dP/dtmax
were significantly greater and
was significantly less in the
phospholamban knockout mice, and
±dP/dtmax was
significantly lower and
significantly greater in the phospholamban
overexpression mice compared with their respective isogenic controls.
|
|
Force-frequency relation.
The effects of incremental atrial pacing on LV
+dP/dtmax in
representative phospholamban knockout and phospholamban overexpression mice along with their respective wild-type littermates are shown in
Fig. 1. Incremental pacing resulted in
significant increases in
+dP/dtmax in both
groups of mice. The average LV
+dP/dtmax increased from 9,800 ± 875 to 15,849 ± 1,100 mmHg/s
(P < 0.05) in the phospholamban
knockout mice compared with 3,300 ± 800 to 5,500 ± 400 mmHg/s
in their wild-type SvJ controls (P < 0.05). Similarly, the average
+dP/dtmax
increased from 5,726 ± 244 to 7,500 ± 400 mmHg/s
(P < 0.05) in the
phospholamban overexpression mice compared with 6,596 ± 580 to
9,700 ± 600 mmHg/s in their FVB/N wild-types controls
(P < 0.05).
|
Strain differences.
There were significant differences in the intrinsic heart rates and
hemodynamic parameters at matched, atrially paced heart rates of 300 beats/min between the two strains of wild-type mice used controls in
these experiments (Table 3).
To determine whether the levels of the SR
Ca2+-ATPase and phospholamban
could account for the variable hemodynamic findings in the 129SvJ and
FVB/N strains of mice, we performed quantitative immunoblotting of
total cardiac homogenates (Fig. 2). Our
results indicate that the levels of phospholamban/SR
Ca2+-ATPase are similar in these
two strains of mice (1.12 vs. 1.04).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The relation between force and the frequency of stimulation is an important determinant of myocardial contractility; the positive inotropic effect of increasing beat frequency has been demonstrated in a variety of preparations including papillary muscles, ventricular muscle strips, whole hearts, and the intact animal (6, 26, 34). The present study indicates that the level of phospholamban [and therefore the magnitude of SR Ca2+ loading (17, 24)] is an important negative determinant of the force-frequency relation and myocardial contractility in the intact closed-chest anesthetized mouse. Another important finding is that frequently measured myocardial contractile parameters are significantly different among various strains of normal mice, emphasizing the importance of using strain-matched littermates for comparative purposes.
Our recent studies have demonstrated that ascending and descending
limbs of the force-frequency relation exist in both anesthetized and
conscious sedated intact animals and that
HRcrit changes directly with the
inotropic state of the heart (12, 20). However, the effects of
-adrenergic receptor stimulation have been controversial (6, 33);
discrepant data may be due to species, methodological, and analytic
differences. Increased stimulation frequency increases Ca2+ entry into the cell per unit
time and reduces the time available for SR
Ca2+ accumulation, ultimately
exhausting the capacity of the SR (9). Thus a decreased ability of the
SR Ca2+-ATPase to resequester
Ca2+ is likely to play a critical
role in the development of the descending limb of the biphasic
force-frequency relation. Our results support this hypothesis insofar
as the onset of the descending limb
(HRcrit) and the magnitude of LV
dP/dtmax are
inversely related to the relative levels of phospholamban/SR
Ca2+-ATPase. Thus with
phospholamban ablation there is an increase and with twofold
overexpression of phospholamban there is a decrease in both the heart
rate and LV
+dP/dtmax at
HRcrit. These data are consistent
with those obtained from thin muscle strips in human heart failure (9)
and in in vivo primates with hyperthyroidism (20); however, these
studies relate changes in force-frequency behavior to transcriptional
and translational changes in Ca2+
cycling proteins in settings where additional combinatorial changes occur. The novel transgenic approach and the protocol we employed are
free of these confounding influences (and others, such as age, species,
stimulation range) and demonstrate unambiguously the effect of
phospholamban levels on the force-frequency relation.
The ascending limb of the force-frequency relation has been attributed to the increased amount of systolic Ca2+ available to the contractile proteins, the net effect of which is to increase release of SR Ca2+ from the ryanodine receptor via a Ca2+-induced Ca2+ release; increased Ca2+ resequestration back into the SR results in increased SR Ca2+ release during subsequent contractions. In contrast, the potential mechanisms underlying the descending limb of the force-frequency relation are poorly understood. One possible explanation is that the decreased duration of the action potential, which occurs with increased stimulation frequency, may decrease the amplitude of the Ca2+ transient and hence cardiac contractility. However, in isolated rat myocytes, changes in the action potential duration have very little effect on the Ca2+ transient and contractility (14). Another possible contributor to the descending limb is the effect of reduced preload (a result of decreased LV filling time) on LV +dP/dt (22). Although our study does not address this possibility directly, the finding that dP/dt increased on the ascending limb despite an HR-induced fall in LVEDP and, more importantly, the highly variable heart rates at which the HRcrit occurred in mice with ablation and overexpression of phospholamban argues against a major contribution of the preload. This is consistent with studies in the isolated ejecting dog heart (3) and intact animal (18, 29) that showed a minimal effect of loading conditions on force-interval behavior. Another possible mechanism relates to the timing and effectiveness of atrial contraction (28). Thus it is likely that these mechanisms (i.e., preload, atrioventricular synchrony) act in concert with a frequency-dependent impairment of Ca2+ cycling to produce the descending limb of the force-frequency relation.
Several compensatory biochemical changes in these genetically altered mice potentially influence the force-frequency relation. In the phospholamban knockout mouse, there is an ~25% reduction in the ryanodine receptor and faster type Ca2+ L-channel inactivation (5, 25); however, both of these would be expected to attenuate, not enhance, the ascending limb of the force-frequency relation. In the phospholamban overexpression mouse, there is a 3.7-fold increase in the Na+/Ca2+ exchanger (36); an increase in activity of this exchanger might contribute to the leftward shift of the force-frequency relation in these mice.
Although strain-related differences are not unusual, the marked differences in hemodynamics and force-interval behavior between the SvJ and FVB/N wild-type mice were unexpected. Accordingly, we postulated that the strain differences resulted from variations in the stoichiometric relationship between phospholamban and the SR Ca2+-ATPase. However, at the protein level, the ratios were similar in the two strains. Thus phospholamban/SR Ca2+-ATPase stoichiometry cannot be the only determinant of the force-frequency relation because the profound strain differences in the HRcrit and LV and dP/dt existed with the same phospholamban/SR Ca2+-ATPase ratio.
The findings of the present study should be interpreted in the context of several potential limitations. First, studies were performed in anesthetized animals; other data suggest that the augmentation of the contractile state due to increased stimulation rate is greater in the anesthetized than conscious state (11). Although the physiological relevance of the force-frequency relation in conscious animals is established, the magnitude of that importance remains controversial (7, 11, 19, 26); nevertheless, the study of frequency-dependent effects in well-characterized models provides insight into the molecular mechanisms underlying these processes (8, 10, 35). Anesthesia also depresses both the intrinsic and critical heart rate; however, anesthesia is unlikely to account for the differences in the force-frequency relations among transgenic mice overexpressing phospholamban, gene-target mice without phospholamban, and their isogenic controls. Second, the contractile parameter we employed (+dP/dtmax) is dependent on the LV end-diastolic volume, which varies with the stimulation frequency. However, this effect did not appear to differ between strains and is unlikely to have significantly influenced our findings. In addition, although relatively load-independent indexes based on time-varying elastance have demonstrated the positive inotropic influence of heart rate (22), these measurements are currently impractical to perform in mice. Moreover, the analytic method employed may influence the result, depending on whether the functional index is velocity (e.g., dP/dtmax) or force (e.g., end-systolic elastance) based (22). Third, because we did not record a simultaneous aortic pressure, it is possible that dP/dtmax occurred after aortic valve opening. However, in a random sample (n = 9) at HRcrit the LV pressure at the time of dP/dtmax did not change (SD 10.4 mmHg) and was at least 25 ± 2.4 mmHg less than the peak LV pressure.
Despite these limitations, we conclude that, in anesthetized closed-chest mice, HRcrit is inversely related to the relative phospholamban-to-SR Ca2+-ATPase ratio, with the HRcrit being the highest for the phospholamban knockout mice (due to disinhibition of the SR Ca2+ pumps) and the lowest in phospholamban overexpressing mice (due to twofold overexpression of phospholamban and the resultant inhibition of unregulated SR Ca2+ pumps). Thus these data indicate that the level of phospholamban is a critical determinant of the force-frequency relation. However, mechanical factors, such as asynchronous atrial contraction, may contribute the appearance of the force-frequency relation. Finally, strain differences suggest that additional, unknown determinants, modulate the force-frequency relation and urge caution when comparing mice that are not isogenic.
| |
ACKNOWLEDGEMENTS |
|---|
We acknowledge the excellent secretarial support of Norma Burns.
| |
FOOTNOTES |
|---|
This work was sponsored in part by an American Heart Association Fellowship Award SW-97-27-F, Specialized Center of Research in Heart Failure, and the National Heart, Lung, and Blood Institute Grants P50-HL-52318-04 and HL-26057.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: B. D Hoit, Div. of Cardiology, Univ. of Cincinnati, PO Box 670542, Cincinnati, OH 45267-0542 (E-mail: hoitb{at}ucmail.uc.edu).
Received 6 October 1998; accepted in final form 2 February 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Anderson, P.,
J. Rankins,
C. Arentzen,
R. Anderson,
and
E. Johnson.
Evaluation of the force-frequency relationship as a descriptor of the inotropic state of canine left ventricular myocardium.
Circ. Res.
39:
832-839,
1976
2.
Bohm, M.,
K. LaRosee,
U. Schmidt,
C. Schulz,
R. H. Schwinger,
and
E. Ermann.
Force-frequency relationship and inotropic stimulation in the nonfailing and failing human myocardium: implications for the medical treatment of heart failure.
Clin. Investig.
70:
421-425,
1992[Medline].
3.
Burkhoff, D.,
D. T. Yue,
M. R. Franz,
W. C. Hunter,
and
K. Sagawa.
Mechanical restitution of isolated perfused canine left ventricles.
Am. J. Physiol.
246 (Heart Circ. Physiol. 15):
H8-H16,
1984.
4.
Christensen, G.,
Y. Wang,
and
K. R. Chien.
Physiological assessment of complex cardiac phenotypes in genetically engineered mice.
Am. J. Physiol.
272 (Heart Circ. Physiol. 41):
H2513-H2524,
1997
5.
Chu, G.,
W. Luo,
J. P. Slack,
C. Tilgmann,
W. E. Sweet,
M. Spindler,
K. W. Saupe,
G. P. Boivin,
C. S. Moravec,
M. A. Matlib,
I. L. Grupp,
J. S. Ingwall,
and
E. G. Kranias.
Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts.
Circ. Res.
79:
1064-1076,
1996
6.
Eising, G.,
H. K. Hammond,
G. A. Helmer,
E. Gilpin,
and
J. J. Ross.
Force-frequency relations during heart failure in pigs.
Am. J. Physiol.
267 (Heart Circ. Physiol. 36):
H2516-H2522,
1994
7.
Freeman, G. L.,
W. C. Little,
and
R. A. O'Rourke.
Influence of heart rate on left ventricular performance in conscious dogs.
Circ. Res.
61:
455-464,
1987
8.
Hasenfuss, G.,
C. Holubarsch,
H. P. Hermann,
K. Astheimer,
B. Pieske,
and
H. Just.
Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy.
Eur. Heart J.
15:
164-170,
1994
9.
Hasenfuss, G.,
H. Reinecke,
R. Studer,
M. Meyer,
B. Pieske,
J. Holtz,
C. Holubarsch,
H. Posival,
H. Just,
and
H. Drexler.
Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+ ATPase in failing and nonfailing human myocardium.
Circ. Res.
75:
434-442,
1994
10.
Hasenfuss, G.,
H. Reinecke,
R. Studer,
B. Pieske,
M. Meyer,
H. Drexler,
and
H. Just.
Calcium cycling proteins and force-frequency relationship in heart failure.
Basic Res. Cardiol.
91:
17-22,
1996.
11.
Higgins, C. B.,
S. F. Vatner,
D. Franklin,
and
E. Braunwald.
Extent of regulation of the heart's contractile state in the conscious dog by alteration in the frequency of contraction.
J. Clin. Invest.
52:
1187-1194,
1973.
12.
Hoit, B. D.,
N. Ball,
and
R. A. Walsh.
Invasive hemodynamics and force-frequency relationships in open- versus closed-chest mice.
Am. J. Physiol.
273 (Heart Circ. Physiol. 42):
H2528-H2533,
1997.
13.
Hoit, B. D.,
and
R. A. Walsh.
In vivo echocardiographic assessment of left ventricular function in transgenic and gene-targeted mice.
Trends Cardiovasc. Med.
7:
129-134,
1997.
14.
Hussain, M.,
G. A. Drago,
J. Colyer,
and
C. H. Orchard.
Rate-dependent abbreviation of Ca2+ transient in rat heart is independent of phospholamban phosphorylation.
Am. J. Physiol.
273 (Heart Circ. Physiol. 42):
H695-H706,
1997
15.
James, J. F.,
T. E. Hewett,
and
J. Robbins.
Cardiac physiology in transgenic mice.
Circ. Res.
82:
407-415,
1998
16.
Kadambi, V. J.,
and
E. G. Kranias.
Phospholamban: a protein coming of age.
Biochem. Biophys. Res. Commun.
239:
1-5,
1997[Medline].
17.
Kadambi, V. J.,
S. Ponniah,
J. M. Harrer,
B. D. Hoit,
G. W. Dorn 2nd,
R. A. Walsh,
and
E. G. Kranias.
Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice.
J. Clin. Invest.
97:
533-539,
1996[Medline].
18.
Kalthof, B.,
N. Sato,
M. Iwase,
Y. Shen,
I. Mirsky,
T. A. Patrick,
and
S. F. Vatner.
Effects of ryanodine on cardiac contraction, excitation-contraction coupling and "treppe" in the conscious dog.
J. Mol. Cell. Cardiol.
27:
2111-2121,
1995[Medline].
19.
Kambayashi, M.,
T. Miura,
B. H. Oh,
H. A. Rockman,
K. Murata,
and
J. Ross, Jr.
Enhancement of the force-frequency effect in myocardial contractility by adrenergic stimulation in conscious dogs.
Circulation
87:
572-580,
1992.
20.
Khoury, S. F.,
B. D. Hoit,
V. Dave,
C. M. Pawloski-Dahm,
Y. Shao,
M. Gabel,
M. Periasamy,
and
R. A. Walsh.
Effects of thyroid hormone on left ventricular performance and regulation of contractile and Ca(2+)-cycling proteins in the baboon. Implications for the force-frequency and relaxation-frequency relationships.
Circ. Res.
79:
727-735,
1996
21.
Koss, K. L.,
and
E. G. Kranias.
Phospholamban: a prominent regulator of myocardial contractility.
Circ. Res.
79:
1059-1063,
1996
22.
Little, W.
The left ventricular dP/dtmax-end-diastolic volume relation in closed chest dogs.
Circ. Res.
56:
808-815,
1985
23.
Lorenz, J.,
and
J. Robbins.
Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse.
Am. J. Physiol.
272 (Heart Circ. Physiol. 41):
H1137-H1146,
1997
24.
Luo, W.,
I. L. Grupp,
J. Harrer,
S. Ponniah,
G. Grupp,
J. J. Duffy,
T. Doetschman,
and
E. G. Kranias.
Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation.
Circ. Res.
75:
401-409,
1994
25.
Masaki, H.,
Y. Sato,
W. Luo,
E. G. Kranias,
and
A. Yatani.
Phospholamban deficiency alters interaction kinetics of L-type Ca2+ channels in mouse ventricular myocytes.
Am. J. Physiol.
272 (Heart Circ. Physiol. 41):
H606-H612,
1997
26.
Miura, T.,
S. Miyazaki,
B. D. Guth,
M. Kambayashi,
and
J. J. Ross.
Influence of the force-frequency relation on left ventricular function during exercise in conscious dogs.
Circulation
86:
563-571,
1992
27.
Mulieri, L. A.,
G. Hasenfuss,
B. Leavitt,
P. D. Allen,
and
N. R. Alpert.
Altered myocardial force-frequency relation in human heart failure.
Circulation
85:
1743-1750,
1992
28.
Palakodeti, V.,
S. Oh,
B. H. Oh,
L. Mao,
M. Hongo,
K. L. Peterson,
and
J. J. Ross.
Force-frequency effect is a powerful determinant of myocardial contractility in the mouse.
Am. J. Physiol.
273 (Heart Circ. Physiol. 42):
H1283-H1290,
1997
29.
Pidgeon, J.,
M. Lab,
A. Seed,
G. Elzinga,
D. Papadoyannis,
and
M. I. Noble.
The contractile state of cat and dog heart in relation to the interval between beats.
Circ. Res.
47:
559-567,
1980
30.
Rockman, H. A.,
D. J. Choi,
S. A. Akhter,
M. Jaber,
B. Giros,
R. J. Lefkowitz,
M. G. Caron,
and
W. J. Koch.
Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice.
J. Biol. Chem.
273:
18180-18184,
1998
31.
Rockman, H. A.,
W. J. Koch,
C. A. Milano,
and
R. J. Lefkowitz.
Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice.
J. Mol. Med.
74:
489-495,
1996[Medline].
32.
Ross, J.,
T. Miura,
M. Kambayashi,
G. P. Eising,
and
K. H. Ryu.
Adrenergic control of the force-frequency relation.
Circulation
92:
2327-2332,
1995
33.
Ryu, K. H.,
N. Tanaka,
N. Dalton,
L. Mao,
H. A. Rockman,
C. A. Milano,
and
J. Ross, Jr.
Force-frequency relations in the failing rabbit heart and responses to adrenergic stimulation.
J. Card. Fail.
3:
27-39,
1997[Medline].
34.
Schwinger, R.,
M. Bohm,
A. Koch,
R. Uhlmann,
P. Uberfuhr,
E. Kreuzer,
B. Reichart,
and
E. Erdmann.
Force-frequency-relation in human atrial and ventricular myocardium.
Mol. Cell. Biochem.
119:
73-78,
1993[Medline].
35.
Schwinger, R. H.,
M. Bohm,
J. Muller-Ehmsen,
R. Uhlmann,
U. Schmidt,
A. Stablein,
P. Uberfurh,
E. Kreuzer,
B. Reichart,
H. J. Eissner,
and
E. Erdmann.
Effect of inotropic stimulation on the native force-frequency relationship in the failing human heart.
Circulation
88:
2267-2276,
1993
36.
Tramuta, D. A.,
V. Kadambi,
N. Ball,
R. Dash,
E. G. Kranias,
R. A. Walsh,
and
B. D. Hoit.
New insights into calcium cycling using post-extrasystolic potentiation in phospholamban overexpression.
J. Am. Coll. Cardiol.
33:
515A,
1999.
37.
Weiss, J. L.,
J. W. Frederickson,
and
M. L. Weisfeldt.
Hemodynamic determinants of the time course of fall in canine left ventricular pressure.
J. Clin. Invest.
58:
751-760,
1976.
This article has been cited by other articles:
![]() |
H. Garcia-Rivello, J. Taranda, M. Said, P. Cabeza-Meckert, M. Vila-Petroff, J. Scaglione, S. Ghio, J. Chen, C. Lai, R. P. Laguens, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1153 - H1160. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ishizaka, R. E. Sievers, B.-Q. Zhu, M. C. Rodrigo, S. Joho, E. Foster, P. C. Simpson, and W. Grossman New technique for measurement of left ventricular pressure in conscious mice Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1208 - H1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, H. R. Brunner, and M. Burnier Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H806 - H814. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Said, L. Vittone, C. Mundina-Weilenmann, P. Ferrero, E. G. Kranias, and A. Mattiazzi Role of dual-site phospholamban phosphorylation in the stunned heart: insights from phospholamban site-specific mutants Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1198 - H1205. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Pall, K. J. Johnson, and G. L. Smith Abnormal contractile activity and calcium cycling in cardiac myocytes isolated from dmpk knockout mice Physiol Genomics, April 16, 2003; 13(2): 139 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nemoto, G. DeFreitas, D. L. Mann, and B. A. Carabello Effects of changes in left ventricular contractility on indexes of contractility in mice Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2504 - H2510. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. MacGowan, C. Du, D. F. Wieczorek, and A. P. Koretsky Compensatory changes in Ca2+ and myocardial O2 consumption in beta -tropomyosin transgenic hearts Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2539 - H2548. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Hoit, V. J. Kadambi, D. A. Tramuta, N. Ball, E. G. Kranias, and R. A. Walsh Influence of sarcoplasmic reticulum calcium loading on mechanical and relaxation restitution Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H958 - H963. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |